-
-
-
Whether it's new onset or established disease, the PCP has an arsenal of diagnostic tests available. The array of tests, however, can be quite daunting in identifying the right test to order, especially in light of sensitivity and specificity, not to mention cost. This issue provides the PCP with a comprehensive survey of the diagnostic tests available, a guide to selection, an estimate of cost, and limitations of each test.
-
-
FDA warnings for existing drugs dominate pharmaceutical news this month. These warnings represent a new push by the FDA to regulate existing drugs for safety after they have been approved for marketing. It also comes at a time when the FDA is cleaning up its advisory committee processes, especially with regard to limiting potential conflict of interest by advisory committee members.
-
A calcium score < 100 eliminates the need for MPS, but patients with a negative MPS often have coronary calcium. These findings imply a potential role for applying CAC screening after MPS among patients manifesting normal MPS.
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine for the treatment of HIV-1 infections.
-
Toenail Chromium in Men With Diabetes and Cardiovascular Disease; Combination of Fenofibrate and Rosiglitazone and HDL Cholesterol; Outcomes for Patients with Diet-Controlled Diabetes
-
-
Use of ß-blockers is associated with reduced risk of
fracture. The magnitude of reduction is similar to that seen with use of thiazides.